Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: rLP2086 Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

NCT01830855
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
rLP2086, Havrix (HAV), Saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 18 Years
Enrollment
3,596 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
62
States / cities
Birmingham, Alabama • Dothan, Alabama • Harrisburg, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Sep 2, 2026, 6:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

NCT03135834
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline, rLP2086, MenACWY-CRM
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
1,610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Fountain Hills, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 2, 2026, 6:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

NCT01768117
View directory record Official record
Conditions
Meningitis, Meningococcal, Serogroup B
Interventions
rLP2086
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 2, 2026, 6:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

NCT01352793
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
rLP2086 vaccine, control
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
5,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
39
States / cities
Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 2, 2026, 6:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

NCT01461980
View directory record Official record
Conditions
Vaccines, Meningococcal Vaccines
Interventions
rLP2086 + MCV4 + Tdap, MCV4 + Tdap + saline, rLP2086 + saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 12 Years
Enrollment
2,648 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
117
States / cities
Birmingham, Alabama • Daphne, Alabama • Chandler, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 2, 2026, 6:30 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

NCT01461993
View directory record Official record
Conditions
Vaccines, Meningococcal Vaccines
Interventions
rLP2086 and Gardasil, rLP2086, Gardasil
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 17 Years
Enrollment
2,499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
87
States / cities
Daphne, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 2, 2026, 6:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

NCT01352845
View directory record Official record
Conditions
Healthy
Interventions
rLP2086, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 25 Years
Enrollment
3,301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
35
States / cities
Mobile, Alabama • Mesa, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 2, 2026, 6:30 AM EDT
Completed Phase 1 Interventional Results available

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

NCT00879814
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
rLP2086 vaccine or control
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Sep 2, 2026, 6:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

NCT01543087
View directory record Official record
Conditions
Meningococcal Infection
Interventions
blood sampling, bivalent rLP2086
Procedure · Drug
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 18 Years
Enrollment
698 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
36
States / cities
Chandler, Arizona • Huntington Beach, California • Paramount, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 2, 2026, 6:30 AM EDT